权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

非酒精性脂肪性肝炎临床研究网络 (NASH CRN)

基本信息

批准号：
10666377
负责人：
Ayako Suzuki
金额：
$ 28.1万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-05-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10666377
关键词：
Address Adult Advanced Development Affect Antioxidants Automobile Driving Bile Acids Biological Markers Cardiovascular system Cells Child Childhood Cholesterol Clinical Clinical Management Clinical Research Clinical Sciences Clinical Trials Diagnosis Diagnostic tests Disease Disease Progression Dyslipidemias Economic Burden Ensure Environmental Risk Factor Epidemic Erinaceidae FDA approved Fibrosis Funding Future Hepatic Stellate Cell Heritability Human Incidence Institutional Review Boards Intervention Knowledge Laboratory Study Ligands Lipids Lipoproteins Liver Liver Fibrosis Liver Regeneration Malignant Neoplasms Mission Monitor Multi-Institutional Clinical Trial National Institute of Diabetes and Digestive and Kidney Diseases Natural History North America Pathogenesis Pathway interactions Patients Pediatric Hospitals Pharmacotherapy Phenotype Population Study Positioning Attribute Prevention Prospective Studies Protocols documentation Public Health Qualifying Recovery Reporting Research Role Scientist Shapes Signal Pathway Signal Transduction Site Testing Translational Research Work adverse outcome atorvastatin burden of illness chronic liver disease clinical application clinical research site cohort cost cost effective cost effective intervention cost effective treatment drug repurposing effective therapy improved innovation insight liver injury liver repair member mortality non-alcoholic fatty liver non-alcoholic fatty liver disease nonalcoholic steatohepatitis novel novel marker personalized medicine prevent prospective randomized placebo controlled trial smoothened signaling pathway success

项目摘要

The epidemic of nonalcoholic steatohepatitis (NASH) will not be constrained without collaborative efforts to identify, prevent, and treat the factors that drive NASH pathogenesis and progression in humans. To address this challenge the NIDDK established the NASH Clinical Research Network (NASH CRN), a consortium devoted to advancing clinical and translational science pertinent to adult and pediatric NASH. The CRN is widely considered to be a leader in the NASH field because it has developed the world’s largest, best-characterized, and longest prospectively-followed cohort of adult and pediatric NASH patients and done several definitive prospective randomized placebo-controlled trials (RCTs) in NASH subjects. Moving forward, the CRN will leverage information generated by this work to advance development of diagnostic tests, biomarkers of disease progression, and safe, cost-effective treatments for NASH. This competitive renewal application from the Duke/Lurie Children’s Hospital site details our site’s plans for the work that we will accomplish during the next funding cycle as CRN members. In addition to our detailed approach to ensure success of all CRN activities (Aim 1), we further propose a new multi-center RCT evaluating atorvastatin as a generic “repurposed” drug for the treatment of NASH (Aim 2) and related translational science to provide mechanistic information about how statins impact NASH (Aim 3). The latter two projects are natural extensions of our earlier CRN studies which demonstrated the importance of Hedgehog, a lipid-regulated signaling pathway, in determining progression of NASH and NASH-related fibrosis. Accomplishment of these Aims will advance NASH CRN missions by further delineating NASH natural history and identifying novel interventions that safely and cost-effectively prevent and treat NASH.

非酒精性脂肪性肝炎（NASH）的流行将不会受到限制，如果没有合作的努力

项目成果

期刊论文数量（20）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.

Fibro-PeN 的开发，一种非酒精性脂肪肝儿童中重度纤维化的临床预测模型。

DOI：
10.1097/hep.0000000000000644
发表时间：
2023
期刊：
Hepatology (Baltimore, Md.)
影响因子：
0
作者：
Wang,Andrew;Blackford,AmandaL;Behling,Cynthia;Wilson,LauraA;Newton,KimberlyP;Xanthakos,StavraA;Fishbein,MarkH;Vos,MiriamB;Mouzaki,Marialena;Molleston,JeanP;Jain,AjayK;Hertel,Paula;HarlowAdams,Kathryn;Schwimmer,JeffreyB
通讯作者：
Schwimmer,JeffreyB

Non-Hispanic Black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype.

即使在控制了临床危险因素和 PNPLA3 基因型后，患有非酒精性脂肪肝的非西班牙裔黑人晚期纤维化、肝硬化和肝脏相关事件的发生率也较低。

DOI：
10.14309/ajg.0000000000002756
发表时间：
2024
期刊：
The American journal of gastroenterology
影响因子：
0
作者：
Samala,Niharika;Xin,Yuchen;Wilson,LauraA;Yates,Katherine;Loomba,Rohit;Hoofnagle,JayH;Chalasani,Naga;NASHClinicalResearchNetwork
通讯作者：
NASHClinicalResearchNetwork

Hedgehog pathway and pediatric nonalcoholic fatty liver disease.

DOI：
10.1002/hep.26230
发表时间：
2013-05
期刊：
HEPATOLOGY
影响因子：
13.5
作者：
Swiderska-Syn, Marzena;Suzuki, Ayako;Guy, Cynthia D.;Schwimmer, Jeffrey B.;Abdelmalek, Manal F.;Lavine, Joel E.;Diehl, Anna Mae
通讯作者：
Diehl, Anna Mae

Reply: To PMID 24849310.

回复：PMID 24849310。